Targets › SPTLC1
1 program from 1 company in 1 trial: 1 Phase 1; Neurology; next expected readout Jun 2031.
Component of the serine palmitoyltransferase multisubunit enzyme (SPT) that catalyzes the initial and rate-limiting step in sphingolipid biosynthesis by condensing L-serine and activated acyl-CoA (most commonly palmitoyl-CoA) to form long-chain bases. The SPT complex is also composed of SPTLC2 or SPTLC3 and SPTSSA or SPTSSB. Within this complex, the heterodimer with SPTLC2 or SPTLC3 forms the catalytic core. (UniProt, O15269)
Open in Phaseline: the race on SPTLC1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Leal Therapeutics | LTX-002 Antisense oligonucleotide (ASO) targeting SPTLC1 mRNA | SPTLC1 | Phase 1 | Amyotrophic Lateral Sclerosis | Jun 2031 |
Amyotrophic Lateral Sclerosis (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.